29.09.2010 • News

Bayer's Yasmin Patent Infringement Claim Dismissed

A U.S. judge on Tuesday dismissed Bayer’s patent lawsuit against Watson Pharmaceuticals and Novartis' Sandoz unit, which are seeking to market generic versions of Bayer's Yasmin birth control pills.

Bayer had alleged that the defendants infringed its patent by seeking U.S. approval to market generic versions of the oral contraceptive. The judge said that Bayer's patent does not claim a use for Yasmin that has been approved by the U.S. Food and Drug Administration.

The company's claim was dismissed "with prejudice," meaning it cannot be brought again.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read